Senhwa Biosciences, Inc. (TPEX:6492)

Market Cap	4.05B
Revenue (ttm)	1.00M
Net Income (ttm)	-297.21M
Shares Out	89.19M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	588,260
Average Volume	144,367
Open	45.60
Previous Close	45.25
Day's Range	45.30 - 47.85
52-Week Range	40.35 - 64.50
Beta	1.01
RSI	64.76
Earnings Date	Mar 13, 2025

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6492

Financial Performance

In 2023, Senhwa Biosciences's revenue was 1.00 million, a change of 0.00% compared to the previous year's 1.00 million. Losses were -296.31 million, -15.25% less than in 2022.